Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 15 Results

Title
Intervention Indication Therapeutic Area Year Actions
CC-486 for maintenance therapy in acute myeloid leukaemia Azacitidine (Vidaza; CC-486) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2020 View  |  Download
Enasidenib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an Isocitrate Dehydrogenase 2 (IDH2) Mutation Enasidenib (Idhifa; AG-221; CC-90007) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2018 View  |  Download
Gilteritinib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an FLT3 Mutation – Second Line Gilteritinib (ASP2215; Xospata; gilteritinib fumarate) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2018 View  |  Download
Glasdegib for Acute Myeloid Leukaemia (AML) – first line Glasdegib (PF-04449913; glasdegib maleate) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2017 View  |  Download
Guadecitabine for Treatment of Naive Acute Myeloid Leukaemia Guadecitabine (SGI-110) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2017 View  |  Download
Histamine dihydrochloride (Ceplene) in combination with low dose interleukin-2 as maintenance treatment for acute myeloid leukaemia Histamine dihydrochloride (Ceplene) , Low-dose aldesluekin Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2019 View  |  Download
Idasanutlin in addition to cytarabine for relapsed or refractory acute myeloid leukaemia Cytarabine , Idasanutlin (RG7388; RO5503781) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2019 View  |  Download
Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older) I-131-Apamistamab (Iomab-B) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2017 View  |  Download
Ivosidenib for acute myeloid leukaemia with IDH1 mutation Ivosidenib (Tibsovo; AG-120) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2018 View  |  Download
Liposomal cytarabine-daunorubicin for treating relapsed or refractory acute myeloid leukaemia in paediatric patients. CPX-351 (Vyxeos Liposomal) (fixed dose combination: Cytarabine; daunorubicin) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2020 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications